Primary Prophylaxis for Spontaneous Bacterial Peritonitis
Patient Selection Criteria
- The American Association for the Study of Liver Diseases recommends primary prophylaxis with norfloxacin 400 mg once daily for cirrhotic patients with ascitic fluid protein <15 g/L who also have advanced liver disease (Child-Pugh ≥9 with bilirubin ≥3 mg/dL) or impaired renal function (creatinine ≥1.2 mg/dL, BUN >25 mg/dL, or sodium ≤130 mEq/L) 1, 2, 3
- Primary prophylaxis is indicated for high-risk patients who meet both of the following criteria: ascitic fluid protein <15 g/L and at least one of the following: Child-Pugh score ≥9 points with serum bilirubin ≥3 mg/dL, impaired renal function: serum creatinine ≥1.2 mg/dL or BUN >25 mg/dL, or hyponatremia: serum sodium ≤130 mEq/L 1, 3, 4, 5, 6
Recommended Antibiotic Regimens
- The European Association for the Study of the Liver recommends norfloxacin 400 mg orally once daily as the preferred first-line option for primary prophylaxis 1, 4, 5
- Ciprofloxacin 500 mg orally once daily is an acceptable alternative, particularly in regions where norfloxacin is unavailable 2, 4, 5, 6
Evidence Supporting Primary Prophylaxis
- A double-blind, placebo-controlled trial demonstrated that norfloxacin reduced the 1-year probability of developing SBP from 61% to 7% and improved 3-month survival from 62% to 94% in patients with severe liver disease (Child-Pugh ≥9, bilirubin ≥3 mg/dL) and ascitic fluid protein <15 g/L 1, 2, 3, 6
- Norfloxacin also reduced the risk of hepatorenal syndrome from 41% to 28% in this patient population 1, 3, 6
Critical Warnings and Pitfalls
- Long-term quinolone use selects for resistant organisms and increases the risk of gram-positive infections, including MRSA 4, 5, 6
- Restrict proton pump inhibitor use in cirrhotic patients, as PPIs may increase SBP risk 2, 3, 6
- Monitor renal function regularly in patients on prophylactic antibiotics and perform diagnostic paracentesis if clinical deterioration occurs 2, 3, 5, 6